| Title |
Minocycline for acute stroke treatment: a systematic review and meta-analysis of randomized clinical trials
|
|---|---|
| Published in |
Journal of Neurology, June 2018
|
| DOI | 10.1007/s00415-018-8935-3 |
| Pubmed ID | |
| Authors |
Konark Malhotra, Jason J. Chang, Arjun Khunger, David Blacker, Jeffrey A. Switzer, Nitin Goyal, Adrian V. Hernandez, Vinay Pasupuleti, Andrei V. Alexandrov, Georgios Tsivgoulis |
| Abstract |
Various randomized-controlled clinical trials (RCTs) have investigated the neuroprotective role of minocycline in acute ischemic stroke (AIS) or acute intracerebral hemorrhage (ICH) patients. We sought to consolidate and investigate the efficacy and safety of minocycline in patients with acute stroke. Literature search spanned through November 30, 2017 across major databases to identify all RCTs that reported following efficacy outcomes among acute stroke patients treated with minocycline vs. placebo: National Institute of Health Stroke Scale (NIHSS), Barthel Index (BI), and modified Rankin Scale (mRS) scores. Additional safety, neuroimaging and biochemical endpoints were extracted. We pooled mean differences (MD) and risk ratios (RR) from RCTs using random-effects models. We identified 7 RCTs comprising a total of 426 patients. Of these, additional unpublished data was obtained on contacting corresponding authors of 5 RCTs. In pooled analysis, minocycline demonstrated a favorable trend towards 3-month functional independence (mRS-scores of 0-2) (RR = 1.31; 95% CI 0.98-1.74, p = 0.06) and 3-month BI (MD = 6.92; 95% CI - 0.92, 14.75; p = 0.08). In AIS subgroup, minocycline was associated with higher rates of 3-month mRS-scores of 0-2 (RR = 1.59; 95% CI 1.19-2.12, p = 0.002; I2 = 58%) and 3-month BI (MD = 12.37; 95% CI 5.60, 19.14, p = 0.0003; I2 = 47%), whereas reduced the 3-month NIHSS (MD - 2.84; 95% CI - 5.55, - 0.13; p = 0.04; I2 = 86%). Minocycline administration was not associated with an increased risk of mortality, recurrent stroke, myocardial infarction and hemorrhagic conversion. Although data is limited, minocycline demonstrated efficacy and seems a promising neuroprotective agent in acute stroke patients, especially in AIS subgroup. Further RCTs are needed to evaluate the efficacy and safety of minocycline among ICH patients. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 50% |
| Mexico | 1 | 13% |
| Pakistan | 1 | 13% |
| Unknown | 2 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 88% |
| Practitioners (doctors, other healthcare professionals) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 85 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 15% |
| Student > Bachelor | 10 | 12% |
| Other | 7 | 8% |
| Researcher | 6 | 7% |
| Student > Master | 6 | 7% |
| Other | 17 | 20% |
| Unknown | 26 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 24% |
| Neuroscience | 14 | 16% |
| Agricultural and Biological Sciences | 5 | 6% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Other | 7 | 8% |
| Unknown | 33 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 November 2021.
All research outputs
#4,661,312
of 25,837,817 outputs
Outputs from Journal of Neurology
#1,130
of 5,075 outputs
Outputs of similar age
#82,051
of 344,128 outputs
Outputs of similar age from Journal of Neurology
#16
of 66 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,075 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,128 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.